Intra-Cellular Therapies Statistics
Share Statistics
Intra-Cellular Therapies has 106.02M shares outstanding. The number of shares has increased by 9.51% in one year.
| Shares Outstanding | 106.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.33% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 99.11M |
| Failed to Deliver (FTD) Shares | 462 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 1.88M, so 1.78% of the outstanding shares have been sold short.
| Short Interest | 1.88M |
| Short % of Shares Out | 1.78% |
| Short % of Float | 1.9% |
| Short Ratio (days to cover) | 4.11 |
Valuation Ratios
The PE ratio is -49.16 and the forward PE ratio is 340.35.
| PE Ratio | -49.16 |
| Forward PE | 340.35 |
| PS Ratio | 14.79 |
| Forward PS | 6.5 |
| PB Ratio | 11.61 |
| P/FCF Ratio | -55.17 |
| PEG Ratio | n/a |
Enterprise Valuation
Intra-Cellular Therapies Inc. has an Enterprise Value (EV) of 6.88B.
| EV / Earnings | -49.29 |
| EV / Sales | 14.82 |
| EV / EBITDA | -43.34 |
| EV / EBIT | -43.19 |
| EV / FCF | -55.31 |
Financial Position
The company has a current ratio of 5.41, with a Debt / Equity ratio of 0.
| Current Ratio | 5.41 |
| Quick Ratio | 5.31 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.24% and return on capital (ROIC) is -26.32%.
| Return on Equity (ROE) | -0.24% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -26.32% |
| Revenue Per Employee | 761.26K |
| Profits Per Employee | -228.97K |
| Employee Count | 610 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.9 |
Taxes
| Income Tax | 636.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 22.32% in the last 52 weeks. The beta is 0.97, so Intra-Cellular Therapies 's price volatility has been higher than the market average.
| Beta | 0.97 |
| 52-Week Price Change | 22.32% |
| 50-Day Moving Average | 84.7 |
| 200-Day Moving Average | 75.43 |
| Relative Strength Index (RSI) | 47.18 |
| Average Volume (20 Days) | 556.40K |
Income Statement
In the last 12 months, Intra-Cellular Therapies had revenue of 464.37M and earned -139.67M in profits. Earnings per share was -1.46.
| Revenue | 464.37M |
| Gross Profit | 430.63M |
| Operating Income | -159.38M |
| Net Income | -139.67M |
| EBITDA | -158.85M |
| EBIT | -159.38M |
| Earnings Per Share (EPS) | -1.46 |
Balance Sheet
The company has 147.77M in cash and 16.94M in debt, giving a net cash position of 130.83M.
| Cash & Cash Equivalents | 147.77M |
| Total Debt | 16.94M |
| Net Cash | 130.83M |
| Retained Earnings | -1.62B |
| Total Assets | 1.32B |
| Working Capital | 1.11B |
Cash Flow
In the last 12 months, operating cash flow was -124.20M and capital expenditures -269.00K, giving a free cash flow of -124.47M.
| Operating Cash Flow | -124.20M |
| Capital Expenditures | -269.00K |
| Free Cash Flow | -124.47M |
| FCF Per Share | -1.3 |
Margins
Gross margin is 9.27K%, with operating and profit margins of -3.43K% and -3.01K%.
| Gross Margin | 9.27K% |
| Operating Margin | -3.43K% |
| Pretax Margin | -2.99K% |
| Profit Margin | -3.01K% |
| EBITDA Margin | -34.21% |
| EBIT Margin | -34.32% |
| FCF Margin | -26.8% |
Dividends & Yields
ITCI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.74% |
| FCF Yield | -1.4% |
Analyst Forecast
The average price target for ITCI is $93.5, which is 11.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $93.5 |
| Price Target Difference | 11.6% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 29.58 |
| Piotroski F-Score | 3 |